Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.

Viking Therapeutics trades near $30 per share versus a $90.89 consensus analyst target, supported by expectations that its dual GLP-1/GIP obesity candidate VK2735 could generate $141 million of revenue in 2028 and $1.3 billion in 2030. Phase 2 injectable VK2735 produced 14.7% peak weight loss in 13 weeks, but cross-trial comparisons with Eli Lilly's 20.9% tirzepatide result at 72 weeks are not directly comparable. The primary investment risk is oral VK2735 tolerability after 20% of phase 2 participants discontinued due to adverse events; Viking is adjusting dose, tablet size and tablet count ahead of an expected Q4 phase 3 start, while injectable phase 3 results are due in late 2027.

Analysis

VKTX is being valued as a de-risked challenger despite its value inflection sitting well beyond the typical biotech holding window. The key issue is not whether obesity demand is large, but whether Viking can produce a differentiated persistence curve at commercially acceptable discontinuation rates; a faster early response has value only if it reduces churn, improves payer adherence metrics, or supports premium pricing. Without that evidence, the oral program is more likely to be judged against oral incretin convenience, tolerability, and manufacturing economics than against injectable efficacy.

The strategic optionality is asymmetric for LLY and NVO: a credible third entrant expands payer leverage and could pressure net pricing before it materially affects their volumes. LLY is better insulated by scale, prescribing inertia, and an established dual-agonist efficacy benchmark; NVO is relatively more exposed if oral convenience becomes the principal competitive axis. A successful oral entrant could also shift value toward obesity-care distributors, telehealth prescribers and adherence infrastructure, but no listed beneficiary offers a clean near-term read-through.

Near term, VKTX is primarily a sentiment/liquidity trade, with highly concentrated bullish sell-side positioning leaving little room for execution disappointments. The first maintenance data and detailed phase-3 oral design are the relevant 1-3 month catalysts: dose selection, titration schedule, tablet burden, and adverse-event discontinuations matter more than another small efficacy headline. Over 6-18 months, competitive standards will likely rise as LLY, NVO, Amgen (AMGN), and other pipeline programs report, increasing the efficacy-and-tolerability bar Viking must clear.

Contrarian view: the market may be underpricing the possibility that a less aggressive dose schedule improves tolerability only by sacrificing the early weight-loss differentiation underpinning the bull case. Conversely, the stock could rerate sharply if management demonstrates that discontinuations normalize while maintaining a clinically meaningful early-response advantage; this is not yet independently verifiable from the available evidence.

Key Decisions for Investors

• Do not initiate a core VKTX long ahead of oral phase-3 design disclosure; treat it as an event watch. Consider a tactical position only if the design shows materially slower titration/lower pill burden and management provides discontinuation targets, with a 3-6 month horizon and a hard thesis stop on renewed adverse-event discontinuation above roughly 15-20%.
• Express competitive-risk asymmetry through a modest long LLY / short NVO pair over 6-12 months rather than a directional obesity bet. LLY has greater commercial execution and dual-agonist validation; cover if NVO demonstrates superior oral persistence, pricing resilience, or prescription-share stabilization.
• For biotech-risk capital, use defined-risk VKTX call spreads dated beyond the next material clinical/design catalyst rather than outright equity. The missing inputs are implied volatility, cash runway after trial spend, and exact catalyst calendar; if volatility already prices a large binary move, remain sidelined.
• Set an alert around payer commentary and obesity-drug net-price trends in LLY/NVO earnings. Evidence of formulary preference for lower-cost oral maintenance, rather than clinical superiority alone, would be the earliest signal that VKTX's addressable market is expanding at incumbents' expense.